Work

Prescribing Patterns for Sodium-Glucose Cotransporter 2 Inhibitors: A Survey of Nephrologists

Year: 2023

Type: article

Abstract: Diabetes mellitus is a leading cause of end-stage kidney disease worldwide. Thirty percent of adults with diabetes have chronic kidney disease (CKD) in the United States.1 Multiple randomized controlled trials have shown that sodium-glucose cotransporter 2 inhibitors (SGLT2i) slow the progression of CKD and prolong the time to dialysis in patients with diabetic CKD and nondiabetic CKD.2,3 Despite the robust evidence from randomized controlled trials, the approval by the US Food and Drug Administration, and the strong recommendation by international organizations such as Kidney Disease Improving Global Outcomes, fewer than 10% of patients with an indication for SGLT2i are prescribed this class of medication.

Source: Kidney International Reports

DOI: 10.1016/j.ekir.2023.05.001

Authors: Tripti Singh, Tingting Li, Didier Mandelbrot, Brad C. Astor, Ali Poyan Mehr

Institutions: University of Wisconsin–Madison, UW Health University Hospital, Washington University in St. Louis, Kaiser Permanente San Francisco Medical Center

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,625